ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG128

Thrombolytic Therapy in Acute Care: A Comprehensive Overview of Therapeutic Approaches and Clinical Outcomes

Lt Col Cecily PJ (Retd)[1]
Principal
Yatharth Institute of Nursing and Allied Sciences, Yatharth Hospital, Greater Noida, U.P.

Mamata Nayak[2]
Assistant Professor
Department of Medical Surgical
Amrita Vishwa Vidyapeetham, College of Nursing,
Faridabad, Haryana

Neetu Kumari Ram[3]
Associate Professor
Department of Mental Health Nursing
Dhanbad School of Nursing, Dhanbad, Jharkhand

Dr Anugrah Thomas[4]
Associate Professor
Department of Medical Surgical Nursing
Vivekanand College of Nursing,
Moradabad, U.P.

Monalisha Pal[*5]
Assistant Professor
Department of Community Health Nursing
Yatharth Institute of Nursing and Allied Sciences,
Yatharth Hospital, Greater Noida U.P.

Abstract:- Thrombolytic therapy is a vital component in the treatment of acute illnesses such as myocardial infarction, ischemic stroke, and pulmonary embolism. Its purpose is to minimize tissue damage and restore perfusion. With an emphasis on the use of tissue plasminogen activator (tPA) and other drugs, the timing of administration, and the related clinical results, this study thoroughly analyses the therapeutic approaches to thrombolysis. Research shows that by lowering death and morbidity, early administration—ideally, during the first few hours after symptom onset—significantly improves outcomes. Treatment options have increased, especially for patients who are not good candidates for systemic thrombolysis, because to developments in thrombolytic drugs and delivery systems, such as catheter-directed thrombolysis and ultrasound-enhanced thrombolysis. It is important to carefully choose and monitor patients receiving thrombolytic treatment since, despite its advantages, it has some contraindications, including the possibility of haemorrhagic consequences. A customized treatment plan is essential to optimize effectiveness while avoiding side effects, as demonstrated by the outcomes of several clinical trials. In Result it should be noted that research is still being done to determine the best ways to employ thrombolytic treatment to enhance patient outcomes in acute care settings.

Keywords:- *Thrombolytic Therapy, Acute Care, Tissue Plasminogen Activator, Ischemic Stroke, Acute Myocardial Infarction, Haemorrhagic Complications.*

I. INTRODUCTION

Thrombolytic therapy, often referred to as fibrinolytic therapy, is the process of dissolving blood clots that have suddenly developed in blood arteries and are preventing blood flow. This treatment is most frequently utilized in acute care settings to address disorders including large pulmonary embolism (PE), ischemic stroke, and acute myocardial infarction (AMI). Thrombolytic treatment aims to improve clinical results, lessen damage, and restore blood flow to the impacted tissues.[1]

In cases of venous and arterial disease, thrombolytic therapy can be utilized either as the only course of treatment or as an adjuvant to surgery. The likelihood of a successful lysis is dependent on the age of the clot, especially in cases of venous thrombosis, when a recent clot is more amenable to lytic treatment. The method of thrombolysis, which involves administering large dosages straight into the clot over brief intervals, is linked to the best success and lowest rates of complications. This method also plays a significant role in determining the result. Techniques that concentrate the lytic agent within the clot, including intraoperative high-dose and isolated-limb therapy, may be more successful with a reduced rate of complications since systemic therapy raises the danger of bleeding from a distant.[2] The purpose of this study is to present a thorough analysis of the treatment modalities utilized in thrombolytic therapy and how they affect patient outcomes.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG128

II. THROMBOLYTIC THERAPY'S MECHANISM OF ACTION

➢ *Plasminogen Activation*
- Thrombolytics function by transforming the inactive precursor plasminogen into the active enzyme plasmin.
- Blood contains the naturally occurring protein called plasminogen, which is mostly attached to fibrin within a clot.

➢ *Plasmin Formation:*
- Plasminogen is transformed into plasmin after it is activated. The main structural element of blood clots, fibrin, is broken down by the proteolytic enzyme plasmin.
- Fibrinolysis is the term for this process.

➢ *Fibrin Degradation:*
- The clot dissolves as a result of plasmin cleaving fibrin into smaller pieces known as fibrin degradation products (FDPs).
- The amount of tissue damage brought on by ischemia is lessened when the clot breaks up and blood flow through the damaged blood artery is restored.

➢ *Particular Agents Thrombolytic:*
- Streptokinase: A bacterial enzyme called streptokinase combines with plasminogen to create a complex that transforms more plasminogen into plasmin. Because it is not fibrin-specific, systemic fibrinolysis may result from it.
- Urokinase: The human enzyme urokinase directly changes plasminogen into plasmin. Moreover, it can cause systemic fibrinolysis and is non-specific.
- Tissue Plasminogen Activator (tPA): An enzyme that exists naturally that attaches to fibrin in the clot and changes plasminogen into plasmin is known as tissue plasminogen activator, or tPA. Tenecteplase, reteplase, and alteplase are a few examples. Because tPA is fibrin-specific, it lowers the risk of systemic bleeding by predominantly activating plasminogen linked to fibrin clots.

➢ *Guidelines and Approval:*

Plasminogen activator inhibitors (PAIs) and alpha-2-antiplasmin inactivate free plasmin to stop excessive clot disintegration and bleeding, thereby closely controlling plasmin's activity.

III. UTILIZING CLINICAL APPLICATIONS

➢ *Acute Myocardial Infarction (AMI):*
- The goal is to release the clot clogging the coronary artery and replenish the heart muscle's blood supply.
- Tissue Plasminogen Activator (tPA) drugs, such as tenecteplase, reteplase, or alteplase, are used.
- Timing: Best results when taken within 12 hours after the beginning of symptoms, preferably within 3–4.5 hours.

➢ *Ischemic stroke*
- Goal: Removing the clot that is obstructing the blood arteries in the brain in order to avoid or reduce brain injury.
- Narcotics Used: Principal thrombolytic agent: alteplase (tPA).
- When to administer: Three to four and a half hours after stroke symptoms appear

➢ *Pulmonary Embolism (PE)*
- The goal is to disintegrate the clot in the pulmonary arteries and get the lungs' blood flow back to normal.
- Medications: streptokinase, reteplase, or alteplase.
- Timing: Usually used when there is substantial right ventricular dysfunction or in circumstances that are life-threatening.

➢ *Deep Vein Thrombosis (DVT)*
- Dissolving clots in deep veins is the goal, particularly in cases where there is a significant danger of embolism or severe symptoms.
- Medication Used: Streptokinase or alteplase may be utilized.
- Timing: Usually applied when anticoagulant medication is not enough on its own.

IV. MONITORING WHILE GIVING TREATMENT

During and after tPA infusion for at least two hours, patients undergoing thrombolytic treatment are required to undergo continuous neurologic and cardiovascular evaluations, with blood pressure monitoring every 15 minutes; after that, the evaluations must be conducted every six hours, then every hour for the following sixteen hours. Vigilant blood pressure monitoring is necessary to avoid problems. When a patient exhibits any indicators of neurologic decline, clinicians should immediately cease thrombolytic treatment and get an emergency computed tomography (CT). Because of the possibility of reperfusion arrhythmias, cardiac monitoring is necessary. To determine if a patient is a good candidate for fibrinolytic treatment and to measure the severity of the stroke, clinicians should collect the patient's National Institutes of Health Stroke Scale (NIHSS) score. If a patient receiving continuing fibrinolytic therapy exhibits any signs of bleeding problems, they must cease using fibrinolytic drugs or anticoagulants very away. The following stage involves implementing supportive measures, such as transfusion of blood factors and volume correction. Protamine sulfate can counteract the heparin effect if the patient is also taking it concurrently.[3,4]

➢ *Toxicity*

Depending on availability and patient comorbidities, fresh frozen plasma (FFP) cryoprecipitate can aid in the restoration of fibrin and coagulation components. Aminocaproic acid's unique activity makes it helpful for the fibrinolytic medicines' reversal of effect. Unless there is a bleeding that poses a serious risk to life, aminocaproic acid shouldn't be administered. It prevents intrinsic physiological fibrinolytic action, which can cause extensive thrombosis and

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG128

possible end-organ damage in several locations. Heparin-induced thrombocytopenia and disseminated intravascular coagulation (DIC) might both get worse with the medication. A platelet counts of less than 100,000/microL indicates the need for platelet transfusion.[5]

➢ *Contraindications*

Not all patients respond well to thrombolytic treatment. There are absolute and relative categories for contraindications:

➢ *Complete Recommendations:*

- Active Bleeding: Recent or ongoing bleeding conditions, such as haemorrhaging inside the brain or bleeding in the gastrointestinal tract.
- Recent Trauma or Surgery: Within the last two to four weeks, there has been a major trauma or surgery.
- Past occurrences of brain bleeding are known as the history of intracranial haemorrhage.
- Known lesions that may bleed are brain tumours or arteriovenous malformations.
- Severe Hypertension: Uncontrollably elevated blood pressure (>185/110 mm Hg, for example).

➢ *Comparative Restrictions:*

- Stroke Recent: Any ischemic stroke has occurred during the last three months (excluding mild strokes).
- Pregnancy: Because of possible hazards to the foetus, especially in the third trimester.
- Liver disease: The risk of bleeding might rise with severe liver impairment.
- Diabetes and Retinopathy: This condition may worsen if you have severe diabetic retinopathy.
- Within the last six months, particularly if continuous, is recent gastrointestinal bleeding.

1. Coagulopathy or the recent usage of anticoagulants are examples of recent bleeding disorders.

V. COMPARATIVE EVALUATION OF CURRENT RESEARCH

Because thrombotic consequences of cardiovascular disease are a major cause of mortality and disability, thrombolysis may have a positive impact on the course of potentially fatal conditions such myocardial infarction, cerebrovascular thrombosis, and venous thromboembolism. Plasminogen, the dormant proenzyme of the blood's fibrinolytic system, is activated by thrombolytic drugs, which then transform it into the proteolytic enzyme plasmin. Plasmin breaks down the fibrin in a blood clot, but it can also weaken healthy haemostatic system components and increase the risk of bleeding. Presently, there are five thrombolytic medicines that are either clinically investigated or authorized for use in patients suffering from acute myocardial infarction. These include anisoylated plasminogen streptokinase activator complex (APSAC), urokinase, recombinant tissue-type plasminogen activator (rt-PA), and single chain urokinase-type plasminogen activator (scu-PA, prourokinase).

The use of streptokinase (and likely urokinase), the first-generation thrombolytic medicines, is linked to significant systemic fibrinogen breakdown and is only modestly effective. Streptokinase is not as efficient as recombinant tissue-type plasminogen activator (rt-PA), a fibrin-specific thrombolytic drug, according to comparative trials conducted in patients with acute myocardial infarction. Although it may be given by bolus injection, the acylated plasminogen streptokinase activator complex (APSAC) exhibits a profile of thrombolytic effectiveness and fibrin-specificity that is comparable to or slightly better than that of streptokinase. Compared to urokinase, single chain urokinase-type plasminogen activator is more fibrin-specific. Since this medication is still in the early stages of clinical research, there are little comparative data available about its safety and effectiveness. Studies using streptokinase, rt-PA, and APSAC have shown reductions in infarct size, preservation of ventricular function, and/or death. Consequently, for early acute myocardial infarction, thrombolytic therapy is likely to become standard treatment.[6]

A. Advancements in Thrombolytic Therapy

➢ *New Thrombolytic Agents:*

- Tissue Plasminogen Activator (tPA): Continued research on optimizing tPA formulations to enhance their efficacy and reduce bleeding risks.
- Tenecteplase: A modified form of tPA with potentially improved properties for treating myocardial infarction, allowing for easier administration.
- Reteplase: Another modified tPA with a faster onset and longer half-life, used in certain myocardial infarction cases.

➢ *Improved Delivery Systems:*

- Catheter-based Systems: Devices that deliver thrombolytics directly to the clot through a catheter, improving local efficacy and reducing systemic bleeding risks.
- Ultrasound-enhanced Thrombolysis: Combining ultrasound with thrombolytic agents to enhance drug delivery and clot dissolution.

➢ *Targeted Therapy:*

- Nanotechnology: Development of nanocarriers that can deliver thrombolytics directly to clots, potentially reducing systemic side effects and improving targeting.
- Biological Markers: Research into biomarkers to identify patients who would benefit most from thrombolytic therapy and predict treatment outcomes.

➢ *Adjunctive Therapies:*

- Antithrombotic Agents: Combining thrombolytics with antiplatelet or anticoagulant therapies to enhance overall clot resolution.
- Reperfusion Strategies: Integration with strategies like percutaneous coronary intervention (PCI) in myocardial infarction for better outcomes.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG128

VI. FUTURE DIRECTIONS

➢ *Personalized Medicine:*
- Genetic and Molecular Profiling: Using genetic information to tailor thrombolytic therapy to individual patients' needs and optimize treatment outcomes.
- Predictive Models: Development of advanced models and algorithms to predict which patients will respond best to thrombolytic therapy.

➢ *Enhanced Safety Profiles:*
- Risk Reduction: Continued research into reducing the risk of bleeding complications associated with thrombolytic therapy.
- Patient Selection: Improved criteria for selecting patients who are most likely to benefit from thrombolytic therapy, including those with contraindications.

➢ *Early Intervention:*
- Pre-Hospital Administration: Investigating the feasibility and safety of administering thrombolytics in pre-hospital settings, such as by paramedics, to reduce time to treatment.

➢ *Expanded Indications:*
- Non-ST-Elevation Myocardial Infarction (NSTEMI): Exploring the use of thrombolytics in NSTEMI and other conditions where their benefit has been less clear.
- Acute Ischemic Stroke: Research into extending the time window for thrombolytic therapy in acute ischemic stroke, potentially allowing treatment beyond the current 4.5-hour window.

➢ *Cost and Accessibility:*
- Cost-Effective Solutions: Development of more cost-effective thrombolytic therapies and delivery systems to improve accessibility in low-resource settings.
- Global Health Initiatives: Efforts to implement thrombolytic therapy protocols in developing countries where access to advanced treatments is limited.

VII. DISCUSSION

A vital component of the treatment of acute myocardial infarction (AMI) and acute ischemic stroke (AIS) has been thrombolytic therapy, namely the administration of tissue plasminogen activator (tPA). When given promptly, its well-documented efficacy in quickly dissolving clots and restoring blood flow results in much lower rates of morbidity and death. According to research by Hacke et al. (2008),[6] early tPA delivery within three hours of the stroke's beginning increased the chance of positive outcomes by 30%, highlighting the crucial role that time plays in the effectiveness of therapy.

Similarly, a meta-analysis conducted in 2014 by Wardlaw et al. confirmed these results, showing that although thrombolytic treatment clearly has advantages, patient selection and monitoring must be done carefully due to the possibility of haemorrhagic transformation and other problems.[7]

In contrast, more recent research has looked at other therapy modalities, such using mechanical thrombectomy in place of or in addition to tPA, especially for patients who come after the usual therapeutic window. According to the DAWN study (Nogueira et al., 2018), individuals who had mechanical thrombectomy within 6 to 24 hours after the beginning of symptoms had considerably better functional results than those who received just medicinal treatment. Treatment approaches have evolved to reflect a deeper knowledge of the pathophysiology of AIS and the realization that a more individualized strategy that combines mechanical intervention and thrombolysis may result in better clinical results for a larger group of patients.[8,9]

The findings from these trials are consistent, which emphasizes the need for a nuanced approach to thrombolytic therapy. The therapeutic strategy should be guided by the patient's features, available resources, and timing in order to maximize benefits and minimize hazards.

VIII. CONCLUSION

With the potential to significantly enhance survival and functional results, thrombolytic therapy is still a mainstay in the treatment of acute thrombotic events, including myocardial infarction, ischemic stroke, and pulmonary embolism. Clinical studies have shown that, when given within the therapeutic window, thrombolytics can dramatically improve neurological outcomes in patients with ischemic stroke and reduce mortality in acute myocardial infarction by up to 30%. Nevertheless, the treatment must be carefully chosen and carried out, taking into account the possibility of bleeding problems, such as cerebral haemorrhage, which affects 5–7% of patients using thrombolytics for ischemic stroke. For this reason, risk stratification and patient selection are essential to optimizing positive outcomes and reducing negative ones. This vital treatment strategy in acute care is still being refined by ongoing research and developments in thrombolytic drugs and delivery systems, such as catheter-directed thrombolysis and more recent recombinant tissue plasminogen activators (rtPAs). To improve the efficacy and safety of thrombolytic treatment, novel approaches such as genetically modified plasminogen activators and nanotechnology-based delivery methods are being studied.

With increased study, it is anticipated that thrombolytics would be used with more precision and customized methods depending on the unique needs of each patient, ultimately leading to better results and lower risks across a wider range of patient groups.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24AUG128

ACKNOWLEDGMENTS

Contributors to this study are much appreciated for their cooperation.

- *Declaration*

This manuscript has been significantly improved by all of the writers who contributed to it. The text's final draft was read and authorized by the authors.

- *Funding*

No part of the study's conception, data gathering, analysis, interpretation, or paper writing was done in collaboration with the funding source.

- *Conflict of Interest*

The research's publication is not linked to any conflicts of interest, according to the authors.

- *Ethical Consideration*

Not Needed for Ethical Approval

REFERENCES

[1]. Ali, M. R., Salim Hossain, M., Islam, M. A., Saiful Islam Arman, M., Sarwar Raju, G., Dasgupta, P., & Noshin, T. F. (2014). Aspect of thrombolytic therapy: a review. TheScientificWorldJournal, 2014, 586510. https://doi.org/10.1155/2014/586510

[2]. Lawrence, P. F., & Goodman, G. R. (1992). Thrombolytic therapy. The Surgical clinics of North America, 72(4), 899–918. https://doi.org/10.1016/s0039-6109(16)45784-1

[3]. Zarar A, Khan AA, Adil MM, Qureshi AI. Anaphylactic shock associated with intravenous thrombolytics. Am J Emerg Med. 2014 Jan;32(1):113.e3-5.

[4]. Takagi T, Kato T, Sakai H, Nishimura Y. Early neurologic improvement based on the National Institutes of Health Stroke Scale score predicts favourable outcome within 30 minutes after undergoing intravenous recombinant tissue plasminogen activator therapy. J Stroke Cerebrovascular Dis. 2014 Jan;23(1):69-74.

[5]. Kaseer H, Sanghavi DK. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 17, 2023. Aminocaproic Acid.

[6]. Collen, D., & Gold, H. K. (1990). New developments in thrombolytic therapy. Advances in experimental medicine and biology, 281, 333–354.

[7]. Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., ... & Toni, D. (2008). Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. The New England Journal of Medicine, 359(13), 1317-1329.

[8]. Wardlaw, J. M., Murray, V., Berge, E., & del Zoppo, G. J. (2014). Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews,

[9]. Nogueira, R. G., Jadhav, A. P., Haussen, D. C., Bonafe, A., Budzik, R. F., Bhuva, P., ... & Jovin, T. G. (2018). Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. The New England Journal of Medicine, 378(1), 11-21.